Daiichi Sankyo launches first DTC ad for Enhertu, representing …
WEB1 day ago · As Daiichi Sankyo and AstraZeneca’s metastatic breast cancer drug Enhertu picks up more label expansions, the companies are targeting patients directly for the first time in messaging efforts.. Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit as a whole — to educate patients about the drug’s expanded uses.
Daiichi, AZ kick off first DTC Enhertu campaign
WEB3 days ago · Daiichi, AZ's first Enhertu DTC campaign kicks off during Thursday Night Football. By Andrea Park Sep 19, 2024 7:00pm. Enhertu Daiichi Sankyo AstraZeneca breast cancer. As Enhertu’s reach ...
Daiichi Sankyo debuts Enhertu ad during Thursday Night Football
WEB2 days ago · The “Not Today” commercial is Daiichi Sankyo’s first DTC campaign for Enhertu as well as the oncology space. “For us it represents a new phase in the life cycle of Enhertu. ... sadness, even concern with the backdrop of the black-and-white context. The patients that we spoke to, when we showed them this ad, many of them said that they ...
Daiichi Sankyo
WEBDaiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world.
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main …
WEB4 days ago · Sept 17 (Reuters) - Daiichi Sankyo (4568.T), opens new tab and Merck (MRK.N), opens new tab said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
DataSource | Daiichi Sankyo - DataSource by Daiichi Sankyo
WEBDataSource for U.S. healthcare professionals to access recently published congress materials and publications from Daiichi Sankyo, including on both approved products and products in development.
File : Daiichi-sankyo logomark.svg - Wikimedia
WEBJul 3, 2018 · Files are available under licenses specified on their description page. All structured data from the file namespace is available under the Creative Commons CC0 License; all unstructured text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.
IR Material FY2024 - IR Library - Investors - Daiichi Sankyo
WEB5 days ago · Daiichi Sankyo is an innovative global healthcare company based in Japan underpinned by its Purpose: “To contribute to the enrichment of quality of life around the world”.
Daiichi Sankyo and MSD Enter into Global Development and ...
WEBAug 6, 2024 · Daiichi Sankyo and MSD to co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where MSD retains exclusive rights.
WEBJun 28, 2024 · With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.
